Johnson and Johnson warns pharma tariffs could cause drug shortages

Stay notified with free updates

Simply sign up Pharmaceuticals sector MEFT Digest – Directly delivered to your inbox.

Johnson and Johnson’s Chief Executive have warned that potential duty drugs in the US industry can be a shortage of drugs.

The industry was excluded from the extensive tariffs announced this month, but the Trump administration has made it clear that it is considering using them to try to increase their home production.

There is currently no tariff on Pharmaceuticals in the United States due to a discount on the World Trade Organization Trade Agreement of the Year.

Joacuin Duato, who led one of the world’s largest pharmas and medical devices companies, said in a call to analysts on Tuesday: “Pharmaceutical tariffs have a reason for zero. Because it can hinder the customs chain, which can lead to lack.”

Medical devices and technologies like surgical robots created by J&J have been hit by new US tariffs.

“If all you want is to create manufacturing power in both Made Tech and Pharmaceuticals, the most effective answer is not tariff, tax policy,” Duato said.

In March, JaNez announced that it would invest $ 55 billion in the new plant in the United States in the next four years, saying that it had increased 25 percent of investment over the previous four years.

Monday, US administration It began investigating the national security effects to depend on drug imports. The investigation began on April 1 and would consult for 21 days.

The two also said that he thought it was important to work with the administration to “alleviate some of the weaknesses in our healthcare supply chain” for health care agencies in response to a question about investigations and possible tariffs.

Jo O Joe Olock, Chief Financial Officer of JO J, says the company “wants to be pending for the administration and their process”.

The pharmaceutical industry is generally refrained from publicly condemning tariffs, hoping that the discussion will prevail behind the screen. However, dwar comments warned on Friday after the Estrogenca Chair Michelle Dimari that the tariffs could damage patients, the health system and “health equity”.

In the results published on Tuesday, despite the factory of $ 400mn at the cost of $ 400mn on most medical devices in J&DJ, the share predicted for 10.50- $ 10.70 years has maintained its adjusted mixed earnings.

In the first quarter of the year, its sales were $ 21.9 billion, which was 2.4 percent higher than the same period last year. Analysts expected $ 21.6 billion.